The Effect of Onabotulinum Toxin-A on Frequency of Headache, Severity of Headache and Health Related Life-Quality at Patients With Resistant Chronic Migraine
Küçük Resim Yok
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Journal Neurological Sciences
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Introduction: Resistant chronic migraine (RCM) causes a considerable decline in the quality of life and work efficiency of the patients and ultimately might even decrease their socioeconomic level because of severe and permanent headaches. In addition, migraine attacks force patients to rush to the emergency rooms, which leads to overcrowding and exhaustion of medical resources. In this study, the effect of onabotulinum toxin A (OBoNT-A) treatment was assessed in terms of efficiency and the quality of life retrospectively at patients with RCM. Method: 15 patients with RCM who were given 155 IU OBoNT-A treatment twice in 12 weeks have been studied retrospectively in terms of change of headache frequency, severity, and the health related quality of life scores (physical function, physical restriction, pain, general health, vitality, social function, emotion and mental health categories) for 24 weeks. Response to treatment is identified as >= 30% decrease in headache frequency while the change in the quality of life was determined with short form-36 before and after treatment. Findings: Average headache frequency was 26.3 day/month before treatment. After 24 weeks, 93% of the patients were responsive to the treatment. After OBoNT-A treatment average headache frequency decreased to 16,6 day/month in 12 weeks and to 17,8 day/month in 24 weeks (p<0.001). Average health related quality of life scores before treatment were under 50%, while all the health related quality of life scores improved after treatment(p<0.001). At the end of 24 weeks, headache severity significantly decreased (p<0.001). Conclusion: OBoNT-A is an effective treatment in patients with RCM and it must be considered a first line treatment for RCM patients considering the cost-effectiveness researches.
Açıklama
Anahtar Kelimeler
Onabotulinum toxin-A, resistant chronic migraine, quality of life
Kaynak
Journal of Neurological Sciences-Turkish
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
32
Sayı
3
